Follow AbCellera Biologics to never miss an important update.
Director John Montalbano purchased about 10,000 shares at a price of roughly $11 each. This follows similar recent purchases by the company's finance chief and another director. While this is a relatively small amount for a company of this size, it shows a cluster of insiders putting their own money into the stock. These purchases come shortly after the company reported successful trial results for one of its drug candidates and raised new cash to fund its operations.
Chief Financial Officer Andrew Booth bought about $384,000 worth of shares. This is an open-market purchase, meaning the executive used his own cash to increase his stake rather than just receiving stock as part of his pay.
When a top executive buys shares after a company raises money and reports positive trial data, it often suggests they believe the stock still has room to run. This adds to a string of recent buys from other leaders at the firm.
Director Michael Hayden purchased approximately $481,000 worth of stock. This is a large open-market buy, which is generally seen as a sign of confidence from someone with an inside view of the company's research pipeline.
This purchase happened around the same time the company reported successful trial results for one of its molecules. It shows that board members are willing to put significant personal capital into the business even after the stock has already seen recent gains.
The company filed paperwork to finalize its recent move to raise $200 million by selling new shares. This filing is a routine step that follows the announcement of a major financing deal. While selling new shares can dilute existing owners, it provides the cash needed to keep developing new drug candidates. The filing confirms the company has secured the extra funding it recently described to the market.
Source: 8-K filing
Truist Financial raised its price target for AbCellera from $12 to $30, a sharp increase that suggests the firm sees much more value in the company's drug discovery engine than it did before. This is well above the average analyst target of $15. While a higher target shows growing confidence in the company's technology and its portfolio of future royalties, it is not a change in the firm's actual rating. For long-term owners, the target itself matters less than the underlying progress of the drug molecules moving through testing that prompted the change.
Source: Truist Financial
The company has beaten analyst estimates in five of the last eight quarters. Management tends to set a bar they can clear, though revenue has dropped significantly as they pivot toward long-term royalties.
| Expectation | |
|---|---|
| EPS | $-0.18 |
| Revenue | $5M |
Follow AbCellera Biologics to get the latest and most important updates.
Follow ABCL